CERC-301 is a selective NR2B specific NMDA receptor antagonist being developed for the treatment of Neurogenic Orthostatic Hypotension (nOH) associated with neurodegenerative diseases such as Parkinson's Disease, Multiple Systems Atrophy and Pure Autonomic Failure. CERC-301 has a rapid onset of action, which we believe will result in long-term effectiveness and fewer side effects than the leading nOH treatments currently available.
CERC-301 is an orally available NR2B specific, NMDA receptor antagonist. NMDA receptor overactivation is associated with many neurodegenerative diseases, including Parkinson's disease. The neural protective attributes of NMDA receptors antagonists, such as CERC-301, may provide a therapeutic benefit to patients with neurodegenerative conditions. Further investigations to fully understand the therapeutic benefits of NMDA receptor antagonists and the exact mechanism of action of CERC-301 are on-going.